小细胞肺癌患者脑转移失败相关的血液学变量
分析2001-2015年293例诊断时无脑转移的小细胞肺癌患者,评估治疗前血液学标志物与无脑转移生存(BMFS)的相关性。中位随访14.3个月,115例(39%)发生脑转移;高血小板计数(PPC>270×10⁹/L)者2年BMFS率14.6%,低于低PPC者22.1%(P=0.009);高PPC与更差BMFS独立相关(P=0.038),接受胸部放疗<45 Gy和未行预防性颅脑照射亦与更差BMFS独立相关(均P<0.001)。
要点
- 高血小板计数(>270×10⁹/L)与更差的无脑转移生存独立相关(P=0.038)。
- 高PPC者2年BMFS率14.6%,低PPC者22.1%(P=0.009)。
- 胸部放疗<45 Gy和未行预防性颅脑照射亦与更差BMFS独立相关(均P<0.001)。
核心结论
- 高血小板计数与诊断时无脑部病变的小细胞肺癌患者脑转移发生率增加相关。
研究设计与样本
- 分析2001-2015年293例诊断时无脑转移、接受化疗和/或胸部放疗的小细胞肺癌患者。
- 评估治疗前血液学标志物(血小板计数、中性粒细胞计数、淋巴细胞计数、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、乳酸脱氢酶)及其他临床特征与无脑转移生存的相关性。
- 采用受试者工作特征曲线确定截断值,单因素分析中显著的因子用于构建无脑转移生存的多因素Cox模型。
主要发现
- 中位随访时间14.3个月,115例(39%)发生脑转移。
- 治疗前低血小板计数(≤270×10⁹/L)者脑转移发生率为32%,高血小板计数(>270×10⁹/L)者为46%。
- 全部患者中位无脑转移生存时间为27.9个月。
- 高血小板计数者2年无脑转移生存率为14.6%,低血小板计数者为22.1%(P=0.009)。
- 高血小板计数与更差的无脑转移生存独立相关(P=0.038);接受胸部放疗<45 Gy和未行预防性颅脑照射亦与更差的无脑转移生存独立相关(均P<0.001)。
关键数值与推荐
- 血小板计数截断值为270×10⁹/L,高血小板计数定义为>270×10⁹/L。
- 高血小板计数者2年无脑转移生存率14.6%,低血小板计数者22.1%(P=0.009)。
- 高血小板计数与更差无脑转移生存独立相关(P=0.038)。
- 接受胸部放疗<45 Gy与更差无脑转移生存独立相关(P<0.001)。
- 未行预防性颅脑照射与更差无脑转移生存独立相关(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We sought factors associated with the development of brain metastases after treatment of small cell lung cancer (SCLC) in patients without brain involvement at diagnosis. METHODS: We analyzed 293 patients with SCLC without brain metastases who received chemotherapy, thoracic radiation therapy (TRT), or both in 2001-2015. Pretreatment hematologic markers (platelet count, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lactate dehydrogenase) and other clinical characteristics were evaluated for correlation with brain metastases-free survival (BMFS). Cutoffs were established with receiver operating characteristics curves. Factors significant in univariate analysis were used to build a multivariate Cox model for BMFS. RESULTS: Median follow-up time was 14.3 months. Brain metastases developed in 115 patients (39%)-32% of those with low pretreatment platelet counts (PPC) (≤270 × 109/L) and 46% of those with high PPC (>270 × 109/L). Median BMFS time for all patients was 27.9 months. Two-year BMFS rates were worse for patients with high PPC (14.6% vs. 22.1% low, P = 0.009). High PPC was independently associated with inferior BMFS (P = 0.038), as were receipt of TRT <45 Gy and no prophylactic cranial irradiation (both P < 0.001). CONCLUSIONS: High PPC was associated with increased rates of brain metastasis in patients with SCLC with no evidence of brain disease at diagnosis.
引用
- Suzuki R, Wei X, Allen PK, et al. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018. PMID: 29907337. doi:10.1016/j.radonc.2018.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。